Physician profile

Neal E Holleran

Internal Medicine · Celina, OH

NPI 1447368766

$2,351.36

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $643.33 2019-2022
E.R. Squibb & Sons, L.L.C. $281.76 2019-2022
Abbvie INC. $236.42 2021-2022
Novo Nordisk INC $126.72 2019-2022
Novartis Pharmaceuticals Corporation $118.40 2019
Takeda Pharmaceuticals U.S.A., INC. $112.88 2019-2022
Astellas Pharma US INC $98.50 2019-2020
Janssen Pharmaceuticals, INC $90.77 2019-2022
Alkermes, INC. $90.33 2020
Abbott Laboratories $81.14 2021-2022
Amgen INC. $80.64 2019
Merck Sharp & Dohme LLC $74.85 2019-2022
Glaxosmithkline, LLC. $70.41 2021-2022
Sanofi-Aventis U.S. LLC $47.38 2019-2022
Otsuka America Pharmaceutical, INC. $38.68 2021-2022
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $38.41 2020-2021
Nestle Healthcare Nutrition INC. $25.10 2021
Pfizer INC. $24.10 2019
Eisai INC. $13.33 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $12.17 2021
Esperion Therapeutics, INC. $12.15 2020
Ultragenyx Pharmaceutical INC. $11.48 2021
Avanir Pharmaceuticals, INC. $11.28 2019
Amarin Pharma, INC. $11.13 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Neal E Holleran

$2,351.36

in general payments reported 2019-2025

Years
2019-2022
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/632012/neal-e-holleran

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.